Skip to main content Skip to section navigation Skip to footer
SCYNEXIS, Inc. SCYNEXIS, Inc.
  • About Us
    • Our Mission
    • Leadership
    • Partnerships
    • Careers
    • Contact Us
  • Our Science
    • Ibrexafungerp
    • Life-threatening Infections
    • Community Infections
    • Pipeline
    • Publications and Presentations
  • Our Product
  • News
    • News
    • Events
  • Careers
  • Investors
    • News & Events
    • Company Info
    • Financial Info
    • Stock Info
    • SEC Filings
    • Governance

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Leadership
    • Contacts
    • FAQ
    • Tear Sheet
  • Financial Info
    • Overview
    • Financial Results
    • Key Ratios
    • Investor Calculator
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Investor Calculator
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Filings
    • Quarterly Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Sep 27, 2023 8:31pm EDT

SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance

Aug 28, 2023 8:00am EDT

SCYNEXIS to Participate in September Investor Conferences

Aug 14, 2023 4:30pm EDT

SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 20, 2023 9:58am EDT

SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China

Jun 21, 2023 7:00am EDT

SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK

Jun 15, 2023 4:10pm EDT

SCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference

May 12, 2023 8:00am EDT

SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)

May 11, 2023 7:00am EDT

SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update

Apr 13, 2023 8:30am EDT

SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark

Mar 31, 2023 8:30am EDT

SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 35
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Scynexis
1 Evertrust Plaza, Jersey City, NJ 07302
(201) 884-5485
Facebook Twitter Linkedin
  • Patents
  • Expanded Access
  • Privacy Policy
  • Disclaimer
  • Sitemap
© 2025 SCYNEXIS, Inc. All Rights Reserved.